Why Fulgent Genetics Stock Temporarily Soared 31% Today

Keith Speights, The Motley Fool
·2 min read
Why Fulgent Genetics Stock Temporarily Soared 31% Today

The genetic testing company reported revenue of $295 million with adjusted earnings of $167.5 million, or $6.20 per share. Fulgent also provided 2021 guidance that projects 90% revenue growth this year. Most of Fulgent's tremendous revenue increase came from its COVID-19 testing business.